精准医疗市场－全球产业规模、份额、趋势、机会及预测（依产品/服务、技术、应用、最终用户、地区及竞争格局划分），2021-2031年

全球精准医疗市场预计将从 2025 年的 1,183.5 亿美元成长到 2031 年的 2,275.4 亿美元，复合年增长率达到 11.51%。

这个领域代表了一种疾病预防和治疗的创新范式，它提供的医疗保健服务充分考虑了基因、环境和生活方式的个体差异。推动这一市场发展的关键因素包括基因测序成本的下降、癌症等复杂慢性疾病的日益增多，以及对副作用较小的标靶治疗的需求不断增长。根据个人化医疗联盟（Personalized Medicine Coalition）预测，美国食品药物管理局（FDA）将在2024年核准18种新的个人化药物，约占新核准治疗性分子实体总数的38%。这项数据印证了该产业正朝着标靶干预的方向发展，与传统疗法相比，标靶干预具有更优的疗效。

然而，该市场面临与报销框架和高昂实施成本相关的重大障碍。保险公司和医疗支付者往往难以製定针对这些昂贵治疗方法的统一核保政策，这主要是由于难以解读基因数据和检验长期成本效益。因此，诊断测试和后续标靶治疗的报销存在财务不确定性，这严重阻碍了精准医疗解决方案在全球医疗体系中的广泛应用，并可能阻碍其普及。

市场驱动因素

次世代定序(NGS) 技术的进步以及由此带来的基因组分析成本下降是精准医疗市场的关键驱动因素。这些技术进步已将基因分析从一项高成本的研究活动转变为常规临床诊断，从而能够广泛检测出可采取行动的突变。根据 3billion.io 预测，到 2024 年，单一人类基因组的定序成本将降至约 600 美元，这将显着降低患者和医疗系统的进入门槛。这种成本的降低导致数据生成量激增，为个人化医疗奠定了坚实的基础。例如，Illumina 公司在 2025 年 6 月报告称，到 2024 年，其平台平均每分钟可完成 10 个人类基因定序，这表明可用于指南治疗决策的基因组数据规模庞大。

同时，人工智慧与巨量资料分析的融合对于实用化海量遗传资讯至关重要。随着基因组和表型数据的不断扩展，人工智慧驱动的工具对于解读复杂数据、识别新型生物标记以及精准预测患者预后至关重要。这种技术协同效应正迅速获得监管部门的核准，并加速其在临床上的应用。根据HealthExec报道，截至2025年7月，美国食品药物管理局（FDA）已核准了1,247总合临床人工智慧演算法，这标誌着计算诊断领域正发生显着转变。监管部门日益增长的认可度正使相关人员能够部署先进的预测模型，并提高个人化治疗的有效性，从而将人工智慧确立为全球精准医疗基础设施的核心支柱。

市场挑战

复杂多变的健保报销环境，加上高昂的实施成本，对全球精准医疗市场的成长构成了重大障碍。医疗服务提供者和支付者往往对昂贵的基因组分析和标靶治疗的经济价值和临床效用存在分歧，导致医疗保险政策难以预测。这种财务上的不确定性阻碍了医疗机构升级诊断基础设施，也使製药研发人员持谨慎态度，担心他们的创新可能不具备商业性可行性。因此，患者往往需要承担高额的自付费用，这极大地限制了这些先进医疗解决方案的普及率。

由于缺乏统一的保险覆盖范围，市场出现了明显的碎片化。根据美国癌症协会癌症控制网络统计，截至2024年，美国仅有16个州立法强制要求对生物标记检测提供全面的保险覆盖，这意味着该国大部分地区的准入通讯协定有限或尚不明确。这种监管上的不一致性迫使企业在复杂的支付方政策中摸索前行，从而减缓了市场准入速度，并限制了精准医疗技术在全球范围内的潜在收入。

市场趋势

液态生物检体在非侵入性疾病监测中的应用日益广泛，正推动临床实践向频繁的基于血液的分子监测转型。这一趋势在肿瘤学领域尤为明显，循环肿瘤DNA分析能够即时追踪微量残存疾病。主要诊断机构报告的检测量快速成长，也反映了该方法的扩充性。根据Natera公司2024财年（截至2025年2月）的财务报告，该公司2024年将进行约528,200例肿瘤检测，较上年增长54.9%。这一快速成长反映出，人们越来越依赖纵向监测，以期比传统影像学方法更早发现復发。

同时，精准医疗的应用范围正扩展至中枢神经系统（CNS）疾病，不再局限于传统的肿瘤治疗领域。这一多元化发展得益于血液生物标记在神经退化性疾病诊断中展现出的显着疗效。这些生物标记为昂贵的PET扫描提供了一种可扩展的替代方案，并有助于筛选适合接受标靶CNS治疗的患者。根据Quest Diagnostics公司2025年4月发布的新闻稿，其新型「AD-Detect」血液检测在2025年美国神经病学会（AAN）年会上发表的研究结果显示，该检测在阿兹海默症病理检测方面达到了91%的敏感度和特异性。如此高的诊断准确率对于精准医疗在神经病学领域的实用化至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球精准医疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品/服务分类（精准医疗平台、精准医疗工具、精准医疗服务）
  • 依技术分类（巨量资料分析、人工智慧、生物资讯学、全基因组定序、伴随诊断、次世代定序、其他）
  • 依应用领域（肿瘤科、心臟科、肺科、神经科、免疫科、其他）
  • 依最终用户划分（製药和生物技术公司、医疗保健IT公司、诊断公司、临床研究机构、研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美精准医疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲精准医疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太精准医疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲精准医疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲精准医疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球精准医疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Illumina
• Thermo Fisher Scientific
• Roche
• Guardant Health
• Foundation Medicine
• Qiagen
• BGI
• IBM Watson Health
• Bio-Rad
• Agilent

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Precision Medicine Market is projected to expand from USD 118.35 Billion in 2025 to USD 227.54 Billion by 2031, achieving a compound annual growth rate of 11.51%. This field represents an innovative paradigm in disease prevention and treatment, tailoring healthcare to account for individual variations in genes, environment, and lifestyle. Key drivers fueling this market include the reduction in genomic sequencing costs, the increasing burden of complex chronic conditions like cancer, and the rising demand for targeted therapies designed to limit adverse drug reactions. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 18 new personalized medicines in 2024, comprising roughly 38% of all newly approved therapeutic molecular entities, a statistic that underscores the industry's shift toward targeted interventions that offer superior efficacy compared to traditional approaches.

However, the market faces significant hurdles regarding reimbursement frameworks and the substantial costs associated with implementation. Insurers and healthcare payers often struggle to formulate consistent coverage policies for these premium therapies, largely due to the difficulty of interpreting genetic data and verifying long-term cost-effectiveness. Consequently, the financial uncertainty surrounding reimbursement for both diagnostic testing and subsequent targeted treatments creates a formidable barrier to access, which threatens to impede the broader integration of precision medicine solutions into global healthcare systems.

Market Driver

The evolution of next-generation sequencing (NGS) and the simultaneous decrease in genomic profiling expenses serve as the primary engines driving the precision medicine market. These technological advancements have transitioned genetic analysis from costly research endeavors to routine clinical diagnostics, enabling the widespread detection of actionable mutations. According to 3billion.io, the cost to sequence a human genome dropped to approximately $600 in 2024, significantly lowering entry barriers for patients and healthcare systems alike. This affordability has triggered a surge in data generation, building a strong foundation for personalized care; for instance, Illumina reported in June 2025 that an average of 10 human genomes were sequenced every minute on their platforms throughout 2024, illustrating the massive scale of genomic data available to guide treatment decisions.

In parallel, the integration of artificial intelligence and big data analytics is essential for operationalizing this extensive genetic information. As genomic and phenotypic datasets grow, AI-driven tools have become indispensable for deciphering complex data, identifying novel biomarkers, and accurately predicting patient outcomes. This technological synergy is rapidly achieving regulatory validation, accelerating its clinical adoption. According to HealthExec, by July 2025, the U.S. Food and Drug Administration had cleared a total of 1,247 clinical artificial intelligence algorithms, signaling a definitive move toward computational diagnostics. This increasing regulatory acceptance enables stakeholders to deploy sophisticated predictive models that enhance the efficacy of personalized therapies, establishing AI as a central pillar of the global precision medicine infrastructure.

Market Challenge

The complex and variable landscape of reimbursement, combined with high implementation costs, presents a major obstacle to the growth of the Global Precision Medicine Market. Healthcare providers and payers often disagree on the economic value and clinical utility of expensive genomic profiling and targeted therapies, resulting in unpredictable coverage policies. This financial instability discourages medical institutions from upgrading their diagnostic infrastructure and causes pharmaceutical developers to hesitate, fearing their innovations may lack commercial viability. Consequently, patients frequently encounter prohibitive out-of-pocket costs, which significantly suppresses the adoption rates of these advanced medical solutions.

This absence of uniform coverage creates measurable fragmentation within the market. According to the American Cancer Society Cancer Action Network, in 2024, only 16 U.S. states had enacted legislation mandating comprehensive insurance coverage for biomarker testing, leaving the majority of the country with restricted or undefined access protocols. Such regulatory inconsistency forces companies to navigate a patchwork of payer policies, delaying market entry and limiting the potential revenue scale of precision medicine technologies globally.

Market Trends

The increasing utilization of liquid biopsy for non-invasive disease monitoring is transforming clinical practice toward frequent, blood-based molecular surveillance. This trend is especially impactful in oncology, where circulating tumor DNA analysis allows for the real-time tracking of minimal residual disease. The scalability of this approach is reflected in the rapid volume growth reported by major diagnostic providers; according to Natera's February 2025 financial results for the full year 2024, the company performed approximately 528,200 oncology tests in 2024, representing a 54.9% increase over the prior year. This surge highlights the growing reliance on longitudinal monitoring to detect recurrence earlier than traditional imaging methods allow.

Simultaneously, the scope of precision medicine is expanding into Central Nervous System (CNS) diseases, moving beyond the market's traditional concentration on oncology. This diversification is driven by the validation of blood-based biomarkers for neurodegenerative conditions, which offer scalable alternatives to expensive PET scans and improve patient identification for targeted CNS therapies. According to a press release from Quest Diagnostics in April 2025 regarding their new AD-Detect Blood Test, research presented at the 2025 AAN Annual Meeting showed that the test achieved 91% sensitivity and specificity in detecting Alzheimer's disease pathology. Such diagnostic fidelity is pivotal for operationalizing precision care within the field of neurology.

Key Market Players

• Illumina
• Thermo Fisher Scientific
• Roche
• Guardant Health
• Foundation Medicine
• Qiagen
• BGI
• IBM Watson Health
• Bio-Rad
• Agilent

Report Scope

In this report, the Global Precision Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Medicine Market, By Products & Services

• Precision Medicine Platforms
• Precision Medicine Tools
• Precision Medicine Services

Precision Medicine Market, By Technology

• Big Data Analytics
• Artificial Intelligence
• Bioinformatics
• Whole Genome Sequencing
• Companion Diagnostics
• NGS
• Others

Precision Medicine Market, By Application

• Oncology
• Cardiology
• Respiratory
• Neurology
• Immunology
• Others

Precision Medicine Market, By End User

• Pharmaceutical and Biotechnology Companies
• Healthcare IT
• Diagnostic Companies
• Clinical Research Organization
• Research Institutes

Precision Medicine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Medicine Market.

Available Customizations:

Global Precision Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Products & Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services)
  • 5.2.2. By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, NGS, Others)
  • 5.2.3. By Application (Oncology, Cardiology, Respiratory, Neurology, Immunology, Others)
  • 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Precision Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Products & Services
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Products & Services
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Precision Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Products & Services
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Precision Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Products & Services
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Precision Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Products & Services
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Precision Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Products & Services
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Precision Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Products & Services
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Precision Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Products & Services
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Precision Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Products & Services
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Precision Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Products & Services
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Precision Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Products & Services
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Products & Services
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Precision Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Products & Services
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Precision Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Products & Services
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Precision Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Products & Services
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Precision Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Products & Services
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Precision Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Products & Services
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Precision Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Products & Services
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Precision Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Products & Services
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Precision Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Products & Services
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Precision Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Products & Services
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Precision Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Products & Services
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Precision Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Products & Services
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Precision Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Products & Services
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific
• 15.3. Roche
• 15.4. Guardant Health
• 15.5. Foundation Medicine
• 15.6. Qiagen
• 15.7. BGI
• 15.8. IBM Watson Health
• 15.9. Bio-Rad
• 15.10. Agilent

16. Strategic Recommendations

17. About Us & Disclaimer